Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115024 · ClinicalTrials.gov registry record · Phase 2
EPAT: Estrogen in the Prevention of Atherosclerosis Trial
A Phase 2 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT00115024 is a Phase 2 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 222 participants.
The verdict
NCT00115024, a Phase 2 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).
Interventions
- DRUG Micronized 17B-estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 1994-04 |
| Est. Completion | 1998-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115024
The ClinicalTrials.gov registry entry for NCT00115024 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Micronized 17B-estradiol is the first listed.
NCT00115024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00115024 about?
NCT00115024 is a clinical study titled "EPAT: Estrogen in the Prevention of Atherosclerosis Trial". The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).
What is the current status of trial NCT00115024?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 1994-04. Estimated completion is 1998-11.
What interventions are being tested in trial NCT00115024?
The interventions under investigation include: Micronized 17B-estradiol (DRUG).
Who is sponsoring clinical trial NCT00115024?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.